Literature DB >> 22983871

Bilateral simultaneous central serous chorioretinopathy in a teenage girl with systemic arterial hypertension.

Ahmad A Alwassia1, Mehreen Adhi, Jay S Duker.   

Abstract

We present a case of bilateral simultaneous central serous chorioretinopathy (CSCR) in a teenage girl with a history of systemic arterial hypertension. A 19-year-old Caucasian female, with a history of systemic arterial hypertension, presented with gradual decrease in her central vision for 1 month. She was diagnosed with bilateral simultaneous CSCR, based on the findings of spectral domain optical coherence tomography (SD-OCT), indocyanine green angiography (ICG), fundus auto-fluorescence, fluorescein angiography and color fundus photographs, which are described. Blood pressure was 134/95 mmHg at presentation. Systemic evaluation failed to reveal a cause for the high blood pressure, and included a panel of blood tests, which were all normal. Her best-corrected visual acuity was 20/30 OD and 20/25 OS. Dilated fundus examination showed normal optic discs and retinal vasculature, with no evidence of hypertensive retinopathy. However, shallow retinal fluid associated with pigmentary changes was noted in the center of both maculae. OCT and ICG findings were consistent with the diagnosis of bilateral CSCR. CSCR can manifest in patients with demographics outside the range of those previously reported. This is the first report of CSCR occurring in a teenage girl, with a history of systemic arterial hypertension. It is important to consider this disease in any patient who has a clinically compatible presentation.

Entities:  

Mesh:

Year:  2012        PMID: 22983871      PMCID: PMC3536924          DOI: 10.1007/s10792-012-9624-3

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  10 in total

1.  Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex.

Authors:  A M Thoelen; P P Bernasconi; C Schmid; E P Messmer
Journal:  Retina       Date:  2000       Impact factor: 4.256

2.  The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT.

Authors:  Andrew Tatham; Adrian Macfarlane
Journal:  J Ocul Pharmacol Ther       Date:  2006-04       Impact factor: 2.671

3.  The long-term outcome of central serous chorioretinopathy.

Authors:  E Y Yap; D M Robertson
Journal:  Arch Ophthalmol       Date:  1996-06

4.  Type A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Trans Am Ophthalmol Soc       Date:  1986

5.  Central serous chorioretinopathy in younger and older adults.

Authors:  R F Spaide; L Campeas; A Haas; L A Yannuzzi; Y L Fisher; D R Guyer; J S Slakter; J A Sorenson; D A Orlock
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

6.  Central serous retinopathy in a 7-year-old girl.

Authors:  S L Fine; S L Owens
Journal:  Am J Ophthalmol       Date:  1980-12       Impact factor: 5.258

7.  The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002.

Authors:  Anna S Kitzmann; Jose S Pulido; Nancy N Diehl; David O Hodge; James P Burke
Journal:  Ophthalmology       Date:  2008-01       Impact factor: 12.079

8.  Central serous chorioretinopathy in endogenous hypercortisolism.

Authors:  E A Bouzas; M H Scott; G Mastorakos; G P Chrousos; M I Kaiser-Kupfer
Journal:  Arch Ophthalmol       Date:  1993-09

9.  [Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects].

Authors:  H C Gäckle; G E Lang; K A Freissler; G K Lang
Journal:  Ophthalmologe       Date:  1998-08       Impact factor: 1.059

10.  Central serous chorioretinopathy occurring in patients 60 years of age and older.

Authors:  H Schatz; D Madeira; R N Johnson; H R McDonald
Journal:  Ophthalmology       Date:  1992-01       Impact factor: 12.079

  10 in total
  1 in total

1.  Increased choroidal blood flow and choroidal thickness in patients with hypertensive chorioretinopathy.

Authors:  Michiyuki Saito; Kousuke Noda; Wataru Saito; Kiriko Hirooka; Yuki Hashimoto; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-14       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.